Related Experiment Video

Updated: May 2, 2026

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.1K

Tislelizumab in perioperative NSCLC: a step toward precision and practicality

Yasuhiro Tsutani1

  • 1Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Chinese Clinical Oncology
|September 2, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Non-small cell lung cancer (NSCLC)adjuvant immunotherapyneoadjuvant immunotherapyperioperative immunotherapy

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K

Related Experiment Videos

Last Updated: May 2, 2026

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies
13:37

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

30.1K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

Articles linked to this work by shared authors, journal, and citation graph.

Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.

International journal of molecular sciences·2026

Preoperative swallowing muscle mass is associated with 1-year skeletal muscle loss and subsequent survival in lung cancer.

Clinical nutrition (Edinburgh, Scotland)·2026

Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206.

Lung cancer (Amsterdam, Netherlands)·2026

Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI).

Clinical lung cancer·2026

Association between preoperative diaphragmatic dome height for overall survival in patients with lung cancer and obstructive ventilatory disorder.

International journal of clinical oncology·2026

Preliminary study on efficacy and safety of pixantrone in relapsed/refractory aggressive B-cell lymphomas: multicenter, retrospective cohort study by Polish Lymphoma Research Group (PLRG).

Chinese clinical oncology·2026

Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.

Chinese clinical oncology·2026

Network pharmacology of Sijunzi decoction in pancreatic cancer.

Chinese clinical oncology·2026

Drug-induced liver injury and acute pancreatitis during trastuzumab therapy in a BRCA1-mutated, HER2-positive breast cancer patient: a case report.

Chinese clinical oncology·2026

Epidemiology, diagnosis, and treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma.

Chinese clinical oncology·2026

Biliary neuroendocrine tumors: a narrative review of current diagnostics and management strategies.

Chinese clinical oncology·2026

Identifying Patients With Prostate Cancer Who Benefit Most From Routine Cardiovascular Specialist Referral.

JACC. CardioOncology·2026

Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a long-term follow-up of the randomized RIVETING trial.

Crohn's & colitis 360·2026

Unrecognized Charcot-Marie-Tooth Disease Unmasked by Chemotherapy-Induced Neurotoxicity.

Cureus·2026

Intraoperative Hemodynamic Management and Cerebral Protection During Awake Craniotomy: Evidence-Based Approaches.

Anesthesiology research and practice·2026

Combined Enzyme-Responsive Nano-Peptide Drug with Photothermal Function for Effective Anti-Hepatocellular Carcinoma in Mice Model.

International journal of nanomedicine·2026

Pathologic Complete Response to Neoadjuvant Dual Checkpoint Blockade with Durvalumab Plus Tremelimumab in Advanced-Stage HCC: A Case Report.

Journal of hepatocellular carcinoma·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us